Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Brequinar
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Brequinar for COVID-19
1
study with
115
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Brequinar studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Brequinar
reduces riskIncreased risk → |
Apr 28 2021 |
et al., NCT04575038 | The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2 |
| 205% higher hospitalization (p=0.49) and 34% worse viral clearance. RCT 115 outpatients in the USA, showing no significant differences with brequinar treatment. | ||
